Mariner’s Boston Scientific BSX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $156M | Buy |
2,484,960
+2,053,754
| +476% | +$164M | 0.18% | 102 |
|
|
2025
Q4 | $41.1M | Buy |
431,206
+17,992
| +4% | +$1.76M | 0.05% | 293 |
|
|
2025
Q3 | $40.3M | Buy |
413,214
+112,459
| +37% | +$11.6M | 0.05% | 282 |
|
|
2025
Q2 | $32.3M | Buy |
300,755
+56,113
| +23% | +$5.68M | 0.05% | 311 |
|
|
2025
Q1 | $24.7M | Buy |
244,642
+68,876
| +39% | +$6.94M | 0.04% | 340 |
|
|
2024
Q4 | $15.7M | Buy |
175,766
+11,030
| +7% | +$971K | 0.03% | 423 |
|
|
2024
Q3 | $13.8M | Buy |
164,736
+7,693
| +5% | +$606K | 0.02% | 447 |
|
|
2024
Q2 | $12.1M | Buy |
157,043
+12,108
| +8% | +$886K | 0.02% | 457 |
|
|
2024
Q1 | $9.93M | Buy |
144,935
+16,171
| +13% | +$1.04M | 0.02% | 512 |
|
|
2023
Q4 | $7.44M | Buy |
128,764
+2,034
| +2% | +$109K | 0.02% | 560 |
|
|
2023
Q3 | $6.69M | Buy |
126,730
+10,214
| +9% | +$536K | 0.02% | 556 |
|
|
2023
Q2 | $6.3M | Buy |
116,516
+510
| +0.4% | +$26.6K | 0.02% | 572 |
|
|
2023
Q1 | $5.8M | Buy |
116,006
+11,885
| +11% | +$560K | 0.02% | 585 |
|
|
2022
Q4 | $4.82M | Buy |
104,121
+6,766
| +7% | +$293K | 0.02% | 616 |
|
|
2022
Q3 | $3.77M | Buy |
97,355
+18,864
| +24% | +$757K | 0.02% | 591 |
|
|
2022
Q2 | $2.93M | Buy |
78,491
+181
| +0.2% | +$7.37K | 0.01% | 610 |
|
|
2022
Q1 | $3.47M | Buy |
78,310
+29,375
| +60% | +$1.27M | 0.01% | 578 |
|
|
2021
Q4 | $2.08M | Buy |
48,935
+13,571
| +38% | +$570K | 0.01% | 651 |
|
|
2021
Q3 | $1.53M | Buy |
35,364
+3,820
| +12% | +$169K | 0.01% | 596 |
|
|
2021
Q2 | $1.35M | Buy |
31,544
+18,025
| +133% | +$758K | 0.01% | 588 |
|
|
2021
Q1 | $523K | Buy |
13,519
+1,808
| +15% | +$68.4K | ﹤0.01% | 733 |
|
|
2020
Q4 | $421K | Sell |
11,711
-4,090
| -26% | -$147K | ﹤0.01% | 700 |
|
|
2020
Q3 | $603K | Sell |
15,801
-1,637
| -9% | -$63.1K | 0.01% | 583 |
|
|
2020
Q2 | $612K | Buy |
17,438
+1,470
| +9% | +$52.9K | 0.01% | 574 |
|
|
2020
Q1 | $521K | Buy |
15,968
+1,119
| +8% | +$43.7K | 0.01% | 578 |
|
|
2019
Q4 | $671K | Buy |
14,849
+2,999
| +25% | +$125K | 0.01% | 572 |
|
|
2019
Q3 | $482K | Buy |
11,850
+779
| +7% | +$33K | 0.01% | 604 |
|
|
2019
Q2 | $476K | Buy |
11,071
+1,115
| +11% | +$42.9K | 0.01% | 740 |
|
|
2019
Q1 | $382K | Buy |
9,956
+1,773
| +22% | +$67.7K | 0.01% | 736 |
|
|
2018
Q4 | $289K | Buy |
8,183
+244
| +3% | +$8.85K | 0.01% | 675 |
|
|
2018
Q3 | $306K | Buy |
+7,939
| New | +$277K | 0.01% | 652 |
|
Other funds holding BSX
VCM
VPM
Mariner's BSX Position: Q1 2026 in Review
Mariner increased its Boston Scientific (BSX) stake by 476% in Q1 2026, buying an estimated $164M and bringing the position to 2,484,960 shares worth $156M. The position accounts for 0.18% of the portfolio, ranked #102.
Mariner first reported a position in BSX in Q3 2018 and has held it in 31 quarters since. 1,664 funds tracked by Wall St. Rank hold BSX as of Q1 2026.
- Mariner held 2,484,960 shares of Boston Scientific worth $156M as of Q1 2026.
- Mariner bought 2,053,754 Boston Scientific shares in Q1 2026, an estimated $164M.
- Boston Scientific made up 0.18% of Mariner's portfolio in Q1 2026, its #102 holding.
- Mariner first reported a position in Boston Scientific in Q3 2018 and has held it in 31 quarters since.
- 1,664 funds tracked by Wall St. Rank held Boston Scientific as of Q1 2026.
Based on Mariner's 13F filing for Q1 2026, filed 13 May 2026.